Skip to contentO
Outlook Therapeutics, Inc.
O
OTLKOutlook Therapeutics, Inc. Q3 2025 · 10-Q
Revenue$1.51M$1.51Mno prior Q3 2024 on file Net Income-$20.15M-$20.15MN/M vs Q3 2024 EPS Diluted-$0.55-$0.55N/M vs Q3 2024 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
Operating Cash Flowderived-$11,901,159N/M Margins · derivedGross margin70.8%
Operating margin-1046.2%
Net margin-1338.8%
ended Jun 30, 2025 · filed Aug 14, 2025 · 45 d after period end